价格

GILEAD SCIENCES PTY LIMITED

LEVEL 28 385 BOURKE STREET, Melbourne, Victoria, 澳大利亚

别名:

gilead sciences pty ltd

概览

试验阶段分布

阶段

试验数

占比

不适用

100.0%

试验状态分布

招募中

100.0%

药物批准

按机构分类的批准

TGA

Therapeutic Goods Administration

药物批准

近期批准

SUNLENCA lenacapavir (as sodium) 300 mg film coated tablet bottle (468505)

TGA

2025-07-11

SUNLENCA lenacapavir (as sodium) 300 mg film coated tablet bottle (468505)

TGA

2025-07-11

HEPCLUDEX bulevirtide (as acetate) 2 mg powder for injection vial (407179)

TGA

2024-07-30

HEPCLUDEX bulevirtide (as acetate) 2 mg powder for injection vial (407179)

TGA

2024-07-30

SUNLENCA lenacapavir (as sodium) 463.5 mg/1.5 mL solution for injection vial (386895)

TGA

2023-03-27

SUNLENCA lenacapavir (as sodium) 300 mg film coated tablet blister pack (392350)

TGA

2023-03-27

SUNLENCA lenacapavir (as sodium) 300 mg film coated tablet blister pack (392350)

TGA

2023-03-27

SUNLENCA lenacapavir (as sodium) 463.5 mg/1.5 mL solution for injection vial (386895)

TGA

2023-03-27

Cellular Therapies - T Cells - Axicabtagene ciloleucel, cryopreserved - T - Yescarta - Gilead Sciences Pty Ltd - Injection, intravenous infusion - Bag (400895)

TGA

2022-12-12

Cellular Therapies - T Cells - Axicabtagene ciloleucel, cryopreserved - T - Yescarta - Gilead Sciences Pty Ltd - Injection, intravenous infusion - Bag (400895)

TGA

2022-12-12

资讯

暂无资讯文章

返回机构列表

GILEAD SCIENCES PTY LIMITED

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（1）

Study of Acquired Viral Mutations in Chronic Hepatitis B Patients on Antihepadnaviral Therapy

药物批准

按机构分类的批准

近期批准

资讯